Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03039335 · ClinicalTrials.gov registry record
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
A clinical trial of Alpha-1 Antitrypsin Deficiency, sponsored by Biocerna.
- Completed
- Registry status
- 43
- Enrollment target
- 1
- Study location
NCT03039335: Completed study of Alpha-1 Antitrypsin Deficiency, sponsored by Biocerna.
NCT03039335 is a study of Alpha-1 Antitrypsin Deficiency that has completed, run by Biocerna. The registered enrollment target is 43 participants, below the 2,340-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03039335, a study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Biocerna.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened clinical status at the time of initial diagnosis.
Primary Outcome
Track the number of subjects enrolled to determine if recruitment strategies need to be altered.
Conditions Studied
Study Locations (1)
Maryland
- Biocerna LLC - Fulton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2018-04-15 |
What the finished NCT03039335 record still lists
NCT03039335 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 2,340-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03039335 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03039335 about?
NCT03039335 is a clinical study titled "The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency". The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened ...
What is the current status of trial NCT03039335?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2016-12-15. Estimated completion is 2018-04-15.
What conditions does trial NCT03039335 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
Who is sponsoring clinical trial NCT03039335?
This trial is sponsored by Biocerna, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03039335 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03039335's enrollment target sits among peer trials
43 15th of 24 higher than 10 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI